Delpacibart zotadirsen
RNA / oligonucleotide
Also known as KPE179, AOC 1044
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
Mid- and late-stage studies completed
This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Duchenne Muscular Dystrophy: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Delpacibart Zotadirsen: this drug | Phase 2 | RNA / oligonucleotide | DMD exon 44 | not yet graded | No reviewed efficacy summary in this indication | |
| Givinostat | Approved | Small molecule | HDAC | Reliable signal | NCT02851797: Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment (Baseline and 18 months): Givinostat 1.27 seconds (Standard Error 0.04) | Placebo 1.48 seconds (Standard Error 0.058) | |
| Deramiocel | Phase 3 | Cell therapy | Cardiac cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| RGX-202 | Phase 2/3 | Gene therapy / editing | Dystrophin (microdystrophin transgene) | not yet graded | No reviewed efficacy summary in this indication | |
| Bampidirsen | Phase 1/2 | RNA / oligonucleotide | DMD exon 53 | not yet graded | No reviewed efficacy summary in this indication | |
| Nivudirsen (BMN 351) | Phase 1/2 | RNA / oligonucleotide | DMD exon 51 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Delpacibart zotadirsen to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.